dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Herranz, Carmen |
dc.contributor.author | Mateo, Francesca |
dc.contributor.author | Baiges, Alexandra |
dc.contributor.author | Ruiz de Garibay, Gorka |
dc.contributor.author | Junza, Alexandra |
dc.contributor.author | Johnson, Simon R |
dc.contributor.author | Revilla Lopez, Eva Maria |
dc.contributor.author | Saez Gimenez, Berta |
dc.contributor.author | Gómez Olles, Susana |
dc.contributor.author | Román Broto, Antonio |
dc.date.accessioned | 2022-04-25T14:16:04Z |
dc.date.available | 2022-04-25T14:16:04Z |
dc.date.issued | 2021-09-07 |
dc.identifier.citation | Herranz C, Mateo F, Baiges A, Ruiz de Garibay G, Junza A, Johnson SR, et al. Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. EMBO Mol Med. 2021 Sep 7;13(9):e13929. |
dc.identifier.issn | 1757-4684 |
dc.identifier.uri | https://hdl.handle.net/11351/7403 |
dc.description | Biomarcador; Histamina; Limfangioleiomiomatosi |
dc.description.sponsorship | This research was supported by AELAM, The LAM Foundation (Seed Grant 2019), Instituto de Salud Carlos III grants PI15/00854, PI18/01029, and ICI19/00047 (co-funded by European Regional Development Fund (ERDF), a way to build Europe), Generalitat de Catalunya SGR grants 2014-364 and 2017-449, the CERCA Program, and ZonMW-TopZorg grant 842002003. C.L.M. acknowledges the financial support (PRA-2017-51 project) of the University of Pisa. A.U.K. is supported by Nottingham Trent University’s Independent Fellowship Scheme. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | EMBO Molecular Medicine;13(9) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Histamina - Receptors |
dc.subject.mesh | Lymphangioleiomyomatosis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Histamine |
dc.subject.mesh | Lung Neoplasms |
dc.title | Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.15252/emmm.202113929 |
dc.subject.decs | linfangioleiomiomatosis |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | histamina |
dc.subject.decs | neoplasias pulmonares |
dc.relation.publishversion | https://doi.org/10.15252/emmm.202113929 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Herranz C, Mateo F, Baiges A, Ruiz de Garibay G] ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat, Barcelona, Spain. [Junza A] Department of Electronic Engineering, Institute of Health Research Pere Virgili (IIPSV), University Rovira i Virgili, Tarragona, Spain. Biomedical Research Network Centre in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. [Johnson SR] Department of Electronic Engineering, Institute of Health Research Pere Virgili (IIPSV), University Rovira i Virgili, Tarragona, Spain. [Revilla-López E, Saez B, Gómez-Ollés S, Roman A] Unitat de Trasplantament Pulmonar, Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34378323 |
dc.identifier.wos | 000683691400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |